- Home
- ROIV
as 02-21-2025 4:00pm EST
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | N/A | City: | HAMILTON HM11 |
| Market Cap: | 8.4B | IPO Year: | N/A |
| Target Price: | $17.93 | AVG Volume (30 days): | 3.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.76 - $13.06 | Next Earning Date: | 02-10-2025 |
| Revenue: | $122,585,000 | Revenue Growth: | 140.04% |
| Revenue Growth (this year): | 15.98% | Revenue Growth (next year): | -29.49% |
Stock Insider Trading Activity of Roivant Sciences Ltd. (ROIV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Venker Eric | ROIV | President & COO | Feb 12 '25 | Sell | $10.48 | 435,425 | $4,561,040.74 | 896,869 | |
| Venker Eric | ROIV | President & COO | Jan 20 '25 | Sell | $11.28 | 100,000 | $1,128,000.00 | 896,869 | |
| Venker Eric | ROIV | President & COO | Dec 27 '24 | Sell | $11.68 | 354,604 | $4,141,662.16 | 896,869 | |
| Sukhatme Mayukh | ROIV | Pres&Chief Investment Officer | Dec 23 '24 | Sell | $12.00 | 886,237 | $10,641,738.95 | 18,836,547 | |
| Venker Eric | ROIV | President & COO | Dec 20 '24 | Sell | $11.49 | 100,000 | $1,149,000.00 | 896,869 | |
| Sukhatme Mayukh | ROIV | Pres&Chief Investment Officer | Dec 18 '24 | Sell | $12.05 | 412,584 | $4,971,637.20 | 18,836,547 |
Latest Roivant Sciences Ltd. News
ROIV Breaking Stock News: Dive into ROIV Ticker-Specific Updates for Smart Investing
TipRanks
10 days ago
Roivant Sciences price target lowered to $12 from $13 at BofA
Simply Wall St.
10 days ago
News Flash: Analysts Just Made A Captivating Upgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) Forecasts
GlobeNewswire
12 days ago
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update
GuruFocus.com
15 days ago
What To Expect From Roivant Sciences Ltd (ROIV) Q3 2025 Earnings
GlobeNewswire
19 days ago
Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care
GlobeNewswire
24 days ago
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025
The Wall Street Journal
a month ago
Vivek Ramaswamy Open to Replacing JD Vance in Senate—if Offered
GlobeNewswire
3 months ago
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
Compare ROIV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ROIV Roivant Sciences Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.